Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma and allergic rhinitis in adults and children as prescribed.

GNH USA supplies Montelukast Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene‑receptor antagonist used in the management of several airway‑related conditions. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Dyspepsia: indigestion or upset stomach. - Nausea: occasional queasiness. - Dizziness: brief light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Anaphylaxis: severe allergic reaction requiring immediate care. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe rash or Stevens‑Johnson syndrome: extensive skin involvement. - Bronchospasm: paradoxical worsening of breathing.

Before initiating therapy, consider the following safety measures. - Monitor neuropsychiatric symptoms: watch for mood changes or depression. - Assess liver function: use caution in patients with hepatic impairment. - Use carefully in severe asthma: not a rescue medication for acute attacks. - Avoid in patients with known hypersensitivity to montelukast or any tablet components. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that may reduce montelukast exposure. - Ketoconazole: potent CYP3A4 inhibitor that can increase drug levels. - Phenobarbital: enzyme inducer that may lower efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect, monitor INR. - Other leukotriene modifiers (e.g., zafirlukast): additive pharmacologic effect. - Beta‑agonists: may require dose adjustment for optimal asthma control.